Next Article in Journal
Effects of Chemical and Physical Enhancement Techniques on Transdermal Delivery of Cyanocobalamin (Vitamin B12) In Vitro
Next Article in Special Issue
Exploring the Correlation Between Lipid Packaging in Lipoplexes and Their Transfection Efficacy
Previous Article in Journal
The Influence of Formulation and Manufacturing Process Parameters on the Characteristics of Lyophilized Orally Disintegrating Tablets
Previous Article in Special Issue
Self-Assembled Lipoplexes of Short Interfering RNA (siRNA) Using Spermine-Based Fatty Acid Amide Guanidines: Effect on Gene Silencing Efficiency
Pharmaceutics 2011, 3(3), 458-473; doi:10.3390/pharmaceutics3030458
Article

Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier

1,* , 1, 2
,
3, 3
,
3, 3, 4, 4
,
5, 6, 6
,
7 and 7
Received: 30 June 2011 / Revised: 25 July 2011 / Accepted: 3 August 2011 / Published: 5 August 2011
(This article belongs to the Special Issue Gene Therapy)
View Full-Text   |   Download PDF [197 KB, 8 August 2011; original version 5 August 2011]   |   Browse Figures

Abstract

Research concerning new targeting delivery systems for pharmacologically active molecules and genetic material is of great importance. The aim of the present study was to investigate the potential of fourth generation (P4) cationic phosphorus-containing dendrimers to bind fluorescent probe 8-anilino-1-naphthalenesulfonate (ANS), anti-neoplastic drug cisplatin, anti-HIV siRNA siP24 and its capability to deliver green fluorescent protein gene (pGFP) into cells. The interaction between P4 and ANS (as the model drug) was investigated. The binding constant and the number of binding centers per one molecule of P4 were determined. In addition, the dendriplex between P4 and anti-HIV siRNA siP24 was characterized using circular dichroism, fluorescence polarization and zeta-potential methods; the average hydrodynamic diameter of the dendriplex was calculated using zeta-size measurements. The efficiency of transfection of pGFP using P4 was determined in HEK293 cells and human mesenchymal stem cells, and the cytotoxicity of the P4-pGFP dendriplex was studied. Furthermore, enhancement of the toxic action of the anti-neoplastic drug cisplatin by P4 dendrimers was estimated. Based on the results, the fourth generation cationic phosphorus-containing dendrimers seem to be a good drug and gene delivery carrier candidate.
Keywords: phosphorus-containing dendrimer; drug delivery; gene delivery; dendriplex characterization; transfection; mesenchymal stem cells; tumor; cisplatin phosphorus-containing dendrimer; drug delivery; gene delivery; dendriplex characterization; transfection; mesenchymal stem cells; tumor; cisplatin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Shcharbin, D.; Dzmitruk, V.; Shakhbazau, A.; Goncharova, N.; Seviaryn, I.; Kosmacheva, S.; Potapnev, M.; Pedziwiatr-Werbicka, E.; Bryszewska, M.; Talabaev, M.; Chernov, A.; Kulchitsky, V.; Caminade, A.-M.; Majoral, J.-P. Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier. Pharmaceutics 2011, 3, 458-473.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert